Jasper Therapeutics Announces Merger with Kira Pharmaceuticals
Combined company positioned to advance portfolio of biologic agents designed to improve outcomes in patients with numerous immunologically-driven disorders Concurrent $132 million private investment…
Read the full articleYou might also wanna read
JSPR: Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals
Related Stocks: JSPR
South Korea’s AimedBio Invests in Inocras, Partners on WGS for Cancer Trials
The companies hope to find patients likely to respond to AimedBio’s antibody-drug conjugates.
An Exploratory Study of Obinutuzumab β in the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Conditions : Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP); Obinutuzumab β Interventions : Drug: Obinutuzumab β Sponsors
Attovia Therapeutics files for Nasdaq IPO to fund immune-disease biologics
Tao Fu's San Carlos biotech is seeking an ATTO listing before disclosing price range, share count or valuation.
Japanese Pharma Firm Takeda Plans US$30mn Investment in Indonesia
Japanese biopharmaceutical firm Takeda will invest up to US$30 million to support the development of Indonesia's plasma medicine industry.
STAT+: Pharmalittle: We’re reading about a Novartis acquisition, Republicans backing clinical trial diversity, and more
Novartis is pushing deeper into antibody-drug conjugate development, paying $1.1 billion upfront to buy Myricx Bio
Comments
Sign in to join the conversation.
No comments yet. Be the first.